April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Vasoactive Intestinal Peptide Modulates ECM Restoration and Promotes Healing after Pseudomonas aeruginosa-Induced Corneal Infection
Author Affiliations & Notes
  • Elizabeth A. Berger
    Anatomy & Cell Biology, Wayne State Univ Sch of Med, Detroit, Michigan
  • Kerry Vistisen
    Anatomy & Cell Biology, Wayne State Univ Sch of Med, Detroit, Michigan
  • Ronald P. Barrett
    Anatomy & Cell Biology, Wayne State Univ Sch of Med, Detroit, Michigan
  • Linda D. Hazlett
    Anatomy & Cell Biology, Wayne State Univ Sch of Med, Detroit, Michigan
  • Footnotes
    Commercial Relationships  Elizabeth A. Berger, None; Kerry Vistisen, None; Ronald P. Barrett, None; Linda D. Hazlett, None
  • Footnotes
    Support  NIH Grants R01EY02986 and P30EY004068
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5820. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth A. Berger, Kerry Vistisen, Ronald P. Barrett, Linda D. Hazlett; Vasoactive Intestinal Peptide Modulates ECM Restoration and Promotes Healing after Pseudomonas aeruginosa-Induced Corneal Infection. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5820.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Studies from our laboratory have demonstrated that vasoactive intestinal peptide (VIP) directly converts the normally susceptible C57/BL/6 (B6) mouse to resistant after P. aeruginosa induced keratitis. Previously, we have shown that VIP regulates cytokine/chemokine production, host inflammatory cell function, adhesion molecule expression and Toll-like receptors (TLRs) and TLR-related molecules, ultimately modulating the inflammatory response. This study examines mechanisms by which VIP influences the healing phase following corneal infection; specifically reconstitution of the extracellular matrix.

Methods: : B6 mice received daily i.p. injections of VIP from -1 through 7 days p.i. Control mice were similarly injected with PBS. Real-time RT-PCR, ELISA and immunohistochemistry (IHC) were used to assess the effects of VIP treatment on ECM reconstitution. In vitro stimulation assays were performed using B6-derived fibroblasts to test the effects of VIP treatment using the aforementioned techniques.

Results: : VIP treatment resulted in disparate expression of ECM components when compared to PBS-treated controls. Analysis revealed that corneas of VIP-treated mice had significantly increased levels for CD44, ITG-α1, ITG-α2, laminin-α1, laminin-γ1, and versican; while others such as COL5A1, COL6A1, COL12A1, COL15A1, ITG-α6, secreted phosphoprotein 1, and extracellular matrix protein 1 were significantly down-regulated when compared to PBS-treated animals.

Conclusions: : VIP treatment down-regulates the expression of molecules associated with the degradation of the matrix, while up-regulating the production of those molecules known to enhance ECM reconstitution and function. In addition, VIP stimulates fibroblasts to express molecules associated with healing. The data from this study suggest that VIP not only in regulates disease pathogenesis, but also functions to restore integrity of the corneal stroma.

Keywords: inflammation • neuropeptides • keratitis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×